BRC Therapeutics

BRC Therapeutics is a biotechnology company focused on developing innovative cancer immunotherapies that restore the immune system's ability to recognize and destroy "cold" tumors. The company's core technology centers on restoring the expression of the Transporter associated with Antigen Processing (TAP), which is frequently downregulated in metastatic cancers, leading to the loss of MHC Class I presentation and immune evasion. By re-introducing TAP via gene therapy, BRC Therapeutics aims to turn "cold" tumors "hot," making them susceptible to T-cell-mediated killing and potentially enhancing the efficacy of existing checkpoint inhibitors. The company is a spin-off from the University of British Columbia and leverages decades of research into antigen processing pathways to address unmet needs in oncology.